Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
- Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients
- LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the
“At AAN, we look forward to sharing our latest research for FINTEPLA in LGS that highlights long-term evidence of its cardiovascular safety profile as well as sustained reduction in drop seizure frequency,” said
The analyses include the FINTEPLA open-label study data (NCT03355209) in LGS at two podium presentations, and authors will be available to discuss the data during a discussion:
- Interim Analysis of Long-Term Safety and Efficacy of FINTEPLA (fenfluramine) in Patients with Lennox-Gastaut Syndrome
Knupp, Scheffer, Ceulemans, et al.
Session S13: Epilepsy/Clinical Neurophysiology (EEG): Antiseizure Medications
Monday, April 4, 2022, at 2:48 PM PT
- Long-Term Cardiovascular Safety of Fenfluramine for Lennox-Gastaut Syndrome: Interim Analysis of Open-Label Safety Study
Agarwal, Farfel, Gammiatoni, et al.
Session S24: Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy
Tuesday, April 5, 2022, at 4:18 PM PT
A poster will also be presented about the impact of FINTEPLA on everyday executive function in patients, as captured using the Behavior Rating Inventory of Executive Function (BRIEF®).
- Fenfluramine Improves Everyday Executive Functioning in Patients With Lennox-Gastaut Syndrome: Analysis of Phase 3 Data
Bishop, Isquith, Gioia, et al.
The abstracts being presented are available on the AAN website and will be available following the meeting on the
About Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome is a rare and devastating lifelong childhood-onset epilepsy that can arise from multiple different causes. LGS is characterized by many different seizure types, including many that result in frequent falls and injuries. The intellectual and behavioral problems associated with LGS, as well as around-the-clock care requirements, add to the complexity of life with this disease.2
About FINTEPLA® (fenfluramine) oral solution
FINTEPLA is approved by the FDA and European Commission for the treatment of seizures associated with Dravet syndrome and is in development in Japan for the treatment of seizures associated with Dravet syndrome. FINTEPLA is also being investigated as a potential treatment for Lennox-Gastaut syndrome (LGS) and other rare and severe childhood-onset epilepsy disorders.
Forward Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed,” and similar expressions are intended to identify forward-looking statements. These statements include: the potential for FINTEPLA to lead to improvement of functioning in patients with LGS; Zogenix’s commercialization plans in the U.S. and Europe; and Zogenix’s plans with respect to its development programs. These statements are based on Zogenix’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix’s business, including, without limitation: the timing and completion of the announced merger between
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | firstname.lastname@example.org
+1 (781) 888-5106 | email@example.com
Source: Zogenix, Inc